Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer

Breast Cancer Research and Treatment

Volumn 112, Issue 3, 2008, Pages 419-427

  Ihnen, M ^a   Muller V ^a   Wirtz, R M ^b   Schroder C ^a   Krenkel, S ^a   Witzel, I ^a   Lisboa, B W ^a   Janicke F ^a   Milde Langosch, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SIEMENS AG   (Germany)

Author keywords

Adhesion molecule; ALCAM; Breast cancer; Predictive factor; Response to chemotherapy

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MESSENGER RNA; METHOTREXATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BREAST NEOPLASMS; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FETAL PROTEINS; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 56549107283     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-007-9879-y     Document Type: Article

References (24)

1. RS Rampaul SE Pinder CW Elstopn 2001 Prognostic and predictive factors in primary breast cancer and their role patient management. The Nottingham Breast Team Eur J Surg Oncol 27 229 238
2. LCLT van Kempen JMDT Nelissen WJG Degen 2001 Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction J Biol Chem 176 25783 25790
3. GWM Swart 2002 Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration Eur J Cell Biol 81 313 321
4. SP Bruder NS Ricalton RE Boynton 1998 Mesenchylam stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation J Bone Mineral Res 13 655 663
5. MA Bowen A Aruffo 1999 Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte adhesion molecule (ALCAM/CD166) interactions Transplant Proc 31 795 796
6. H Fujiwara K Tatsumi K Kosaka 2003 Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166) J Clin Endocrinol Metab 88 3437 3443
7. O Ohneda K Ohneda F Arai 2001 ALCAM (CD166): its role in hematopoietic and endothelial development Blood 98 2134 2142
8. J King S Ofori-Acquah T Stevens 2004 Potential role for activated leukocyte cell adhesion molecule and neural cadherin in metastasis to the lung microcirculation Chest 125 150S 151S
9. GWM Swart PC Lunter JWJ van Kilsdonk 2005 Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Met Rev 24 223 236
10. G Kristiansen C Pilarsky C Wissmann 2003 ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions Prostate 54 34 43
11. W Weichert T Knosel J Bellach 2004 ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival J Clin Pathol 57 1160 1164
12. A Verma NK Shukla SV Deo 2005 MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma Oncology 68 462 470
13. JA King SF Ofori-Acquah T Stevens 2004 Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator Breast Cancer Res 6 R478 487
14. A Jezierska WP Olszewski J Pietruszkiewicz 2006 Activated cell adhesion molecule (ALCAM) is associated with suppression of breast cancer cells invasion Med Sci Monit 12 BR245 BR256
15. M Burkhardt E Mayordomo K-J Winzer 2006 Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer J Clin Pathol 59 403 409
16. A-M Bamberger C Methner BW Lisboa 1999 Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype Int J Cancer 84 553 558
17. P Dalerba SJ Dylla I-K Park 2007 Phenotypic characterization of human colorectal cancer stem cells Proc Natl Acad Sci 104 10158 10163
18. A Jezierska W Matysiak T Motyl 2006 ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy Med Sci Monit 12 BR263 BR273
19. S Paik G Tang S Shak 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726 3734
20. JC Chang EC Wooten A Tsimelzon 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 363 362 369
21. M Ayers WF Symmans J Stec 2004 Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophoyphamide chemotherapy in breast cancer J Clin Oncol 22 2284 2293
22. RA Blaheta FH Daher M Michaelis 2006 Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression BMC Cancer 6 294
23. H Kajiyama K Shibata M Terauchi 2007 Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells Int J Oncol 31 2 277 283
24. PC Lunter JW van Kilsdonk H van Beek 2005 Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity Cancer Res 65 8801 8808